High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas

Genes Chromosomes and Cancer

Volumn 42, Issue 3, 2005, Pages 228-237

  Benetkiewicz, Magdalena ^a   Wang, Yun ^b   Schaner, Marci ^c   Wang, Pei ^c   Mantripragada, Kiran K ^a   Buckley, Patrick G ^a   Kristensen, Gunnar ^b   Børresen Dale, Anne Lise ^b   Dumanski, Jan P ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA;

ADULT; AGED; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE; CHROMOSOME 22; CHROMOSOME 22Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CLINICAL ARTICLE; DNA DETERMINATION; DNA MICROARRAY; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HETEROZYGOSITY; HIGH RESOLUTION GENE COPY NUMBER; HUMAN; HUMAN TISSUE; MONOSOMY; MONOSOMY 22; OVARY CARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 22; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROZYGOTE; HUMANS; MIDDLE AGED; MONOSOMY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 12844284659     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20128     Document Type: Article

References (32)

1. Ahonen M, Poukkula M, Baker AH, Kashiwagi M, Nagase H, Eriksson JE, Kahari VM. 2003. Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene 22:2121-2134.
2. Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC. 1999. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 79:1347-1355.
3. Baker VV, Borst MP, Dixon D, Hatch KD, Shingleton HM, Miller D. 1990. c-myc Amplification in ovarian cancer. Gynecol Oncol 38:340-342.
4. Bauknecht T, Angel P, Kohler M, Kommoss F, Birmelin G, Pfleiderer A, Wagner E. 1993. Gene structure and expression analysis of the epidermal growth factor receptor, transforming growth factor-alpha, myc, jun, and metallothionein in human ovarian carcinomas. Classification of malignant phenotypes. Cancer 71:419-429.
5. Bryan EJ, Watson RH, Davis M, Hitchcock A, Foulkes WD, Campbell IG. 1996. Localization of an ovarian cancer tumor suppressor gene to a 0.5-cM region between D22S284 and CYP2D, on chromosome 22q. Cancer Res 56:719-721.
6. Bryan EJ, Thomas NA, Palmer K, Dawson E, Englefield P, Campbell IG. 2000. Refinement of an ovarian cancer tumour suppressor gene locus on chromosome arm 22q and mutation analysis of CYP2D6, SREBP2 and NAGA. Int J Cancer 87:798-802.
7. Buckley PG, Mantripragada KK, Benetkiewicz M, Tapia-Paez I, Diaz De Stahl T, Rosenquist M, Ali H, Jarbo C, De Bustos C, Hirvela C, Sinder Wilen B, Fransson I, Thyr C, Johnsson BI, Bruder CE, Menxel U, Hergersberg M, Mandahl N, Blennow E, Wedell A, Beare DM, Collins JE, Dunham I, Albertson D, Pinkel D, Bastian BC, Faruqi AF, Lasken RS, Ichimura K, Collins VP, Dumanski JP. 2002. A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications. Hum Mol Genet 11:3221-3229.
8. Castells A, Gusella JF, Ramesh V, Rustgi AK. 2000. A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. Cancer Res 60:2836-2839.
9. Cliby W, Ritland S, Hartmann L, Dodson M, Halling KC, Keeney G, Podratz KC, Jenkins RB. 1993. Human epithelial ovarian cancer allelotype. Cancer Res 53:2393-2398.
10. Englefield P, Foulkes WD, Campbell IG. 1994. Loss of heteroxygosity on chromosome 22 in ovarian carcinoma is distal to and is not accompanied by mutations in NF2 at 22q12. Br J Cancer 70:905-907.
11. Fu H, Subramanian RR, Masters SC. 2000. 14-3-3 Proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 40:617-647.
12. Geisler JP, Goodheart MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA, Buller RE. 2003. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer 98:2199-2206.
13. Hirano A, Emi M, Tsuneizumi M, Utada Y, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G, Haga S, Kajiwara T, Nakamura Y. 2001. Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3. and 22q13 correlate with postoperative recurrence in breast cancer. Clin Cancer Res 7:876-882.
14. Iida A, Kurose K, Isobe R, Akiyama F, Sakamoto G, Yoshimoto M, Kasumi K, Nakamura Y, Emi M. 1998. Mapping of a new target region of allelic loss to a 2-cM interval at 22q13.1 in primary breast cancer. Genes Chromosomes Cancer 21:108-112.
15. Jong YJ, Li LH, Tsou MH, Chen YJ, Cheng SH, Wang-Wuu S, Tsai SF, Chen CM, Huang AT, Hsu MT, Lin CH. 2004. Chromosomal comparative genomic hybridization abnormalities in early- and late-onset human breast cancers: correlation with disease progression and TP53 mutations. Cancer Genet Cytogenet 148:55-65.
16. Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T, Nakano H. 2003. Histological classification of ovarian cancer. Med Electron Microsc 36:9-17.
17. Kmet LM, Cook LS, Magliocco AM. 2003. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer 97:384-404.
18. Moynihan TP, Cole CG, Dunham I, O'Neil L, Markham AF, Robinson PA. 1998. Fine-mapping, genomic organization, and transcript analysis of the human ubiquitin-conjugating enzyme gene UBE2L3. Genomics 51:124-127.
19. Pao GM, Janknecht R, Ruffner H, Hunter T, Verma IM. 2000. CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc Natl Acad Sci USA 97:1020-1025.
20. Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, Jeffrey SS, Botstein D, Brown PO. 1999. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 23:41-46.
21. Seidman JD, Kurman RJ. 2003. Pathology of ovarian carcinoma. Hematol Oncol Clin North Am 17:909-925.
22. Sonoda G., Palazzo J, du Manoir S, Godwin AK, Feder M, Yakushiji M, Testa JR. 1997. Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosomes Cancer 20:320-328.
23. Sutherland GR, Baker E, Hyland VJ, Callen DF, Stahl J, Gough NM. 1989. The gene for human leukemia inhibitory factor (LIF) maps to 22q12. Leukemia 3:9-13.
24. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, Birrer MJ. 1993. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 53:3103-108.
25. Wang P, Kim Y, Pollack J, Narasimhan B, Tibshirani R. 2004. A method for calling gains and losses in array CGH data. Biostatistics, in press.
26. Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Trope CG, Abeler VM, Nesland JM, Borresen-Dale AL, Helland A. 2004. Effect of the codon 72 polymorphism (e.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat 24:21-34.
27. Watanabe T, Imoto I, Kosugi Y, Ishiwata I, Inoue S, Takayama M, Sato A, Inazawa J. 2001. A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization. Gynecol Oncol 81:172-177.
28. Wenham RM, Lancaster JM, Berchuck A. 2002. Molecular aspects of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 16:483-497.
29. Wu R, Lin L, Beer DG, Ellenson LH, Lamb BJ, Rouillard JM, Knick R, Hanash S, Schwartz DR, Fearon ER, Cho KR. 2003. Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas. Am J Pathol 162:1603-1610.
30. Yaegashi S, Sachse R, Ohuchi N, Mori S, Sekiya T. 1995. Low incidence of a nucleotide sequence alteration of the neurofibromatosis 2 gene in human breast cancers. Jpn J Cancer Res 86:929-933.
31. Yaffe MB. 2002. How do 14-3-3 proteins work?-Gatekeeper phosphorylation and the molecular anvil hypothesis. FEBS Lett 513:53-57.
32. Zweemer RP, Shaw PA, Verheijen RM, Ryan A, Berchuck A, Ponder BA, Risch H, McLaughlin JR, Narod SA, Menko FH, Kenemans P, Jacobs IJ. 1999. Accumulation of p53 protein is frequent in ovarian cancers associated with BKCA1 and BRCA2 germline mutations. J Clin Pathol 52:372-375.